Ultragenyx Pharmaceutical (RARE) Quick Ratio: History & Chart

Ultragenyx Pharmaceutical Inc.(RARE)

Biotechnology · Novato, CA

$14.46-0.04 (-0.28%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Novato, CA

1,371 employees

www.ultragenyx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Emil D. Kakkis

View full financials

RARE Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

1.56

QUICK RATIO (ACID-TEST) AVG TTM

1.96

QUICK RATIO (ACID-TEST) AVG 3Y

2.34

QUICK RATIO (ACID-TEST) AVG 5Y

2.78

QUICK RATIO (ACID-TEST) AVG 10Y

5.33

QUICK RATIO (ACID-TEST) AVG 15Y

N/A

QUICK RATIO (ACID-TEST) AVG 20Y

N/A

CURRENT VS TTM AVG

-20.38%

CURRENT VS 3Y AVG

-33.37%

CURRENT VS 5Y AVG

-43.96%

CURRENT VS 10Y AVG

-70.78%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

3.35

median of 871 covered companies

CURRENT VS SECTOR MEDIAN

-53.48%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Ultragenyx Pharmaceutical Inc. (RARE)	$1.42B	1.56	1.96	2.34	2.78
AnaptysBio, Inc. (ANAB)vs ›	$1.42B	5.61	9.29	11.65	16.84
Certara, Inc. (CERT)vs ›	$1.44B	2.55	2.09	2.53	2.95
Taysha Gene Therapies, Inc. (TSHA)vs ›	$1.40B	17.76	8.82	5.82	10.42
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.40B	11.11	12.01	12.01	12.01
Braveheart Bio, Inc. (BRVE)vs ›	$1.40B	N/A	N/A	N/A	N/A
Healthcare Services Group, Inc. (HCSG)vs ›	$1.45B	2.94	3.04	2.84	2.90
The Pennant Group, Inc. (PNTG)vs ›	$1.39B	1.20	1.17	1.13	1.04
Maze Therapeutics, Inc. (MAZE)vs ›	$1.46B	18.31	12.63	8.12	8.12
GH Research PLC (GHRS)vs ›	$1.48B	28.70	25.68	28.23	39.61

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Ultragenyx Pharmaceutical Inc. (RARE)

$1.42B

1.56

1.96

2.34

2.78

AnaptysBio, Inc. (ANAB)vs ›

$1.42B

5.61

9.29

11.65

16.84

Certara, Inc. (CERT)vs ›

$1.44B

2.55

2.09

2.53

2.95

Taysha Gene Therapies, Inc. (TSHA)vs ›

$1.40B

17.76

8.82

5.82

10.42

Kailera Therapeutics, Inc. (KLRA)vs ›

$1.40B

11.11

12.01

Braveheart Bio, Inc. (BRVE)vs ›

$1.40B

N/A

Healthcare Services Group, Inc. (HCSG)vs ›

$1.45B

2.94

3.04

2.84

2.90

The Pennant Group, Inc. (PNTG)vs ›

$1.39B

1.20

1.17

1.13

1.04

Maze Therapeutics, Inc. (MAZE)vs ›

$1.46B

18.31

12.63

8.12

GH Research PLC (GHRS)vs ›

$1.48B

28.70

25.68

28.23

39.61

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Ultragenyx Pharmaceutical Inc. (RARE)?

The quick ratio (acid-test) for RARE stock is 1.56.

Is Ultragenyx Pharmaceutical Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 1.56 is 44% below its 5-year average of 2.78, near the low end of its 5-year range (1.56–7.35).

What is the TTM average quick ratio (acid-test) for Ultragenyx Pharmaceutical Inc. (RARE)?

The TTM average quick ratio (acid-test) for RARE stock is 1.96.

What is the 3Y average quick ratio (acid-test) for Ultragenyx Pharmaceutical Inc. (RARE)?

The 3Y average quick ratio (acid-test) for RARE stock is 2.34.

What is the 5Y average quick ratio (acid-test) for Ultragenyx Pharmaceutical Inc. (RARE)?

The 5Y average quick ratio (acid-test) for RARE stock is 2.78.

What is the 10Y average quick ratio (acid-test) for Ultragenyx Pharmaceutical Inc. (RARE)?

The 10Y average quick ratio (acid-test) for RARE stock is 5.33.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	1.56
2026-03-31	1.85
2025-12-31	2.34
2025-09-30	1.74
2025-06-30	2.30
2025-03-31	2.24
2024-12-31	2.24
2024-09-30	2.65
2024-06-30	3.39
2024-03-31	2.28
2023-12-31	2.49
2023-09-30	2.23
2023-06-30	2.76
2023-03-31	3.39
2022-12-31	3.28
2022-09-30	4.36
2022-06-30	2.98
2022-03-31	4.12
2021-12-31	4.63
2021-09-30	6.12
2021-06-30	7.35
2021-03-31	8.33
2020-12-31	6.76
2020-09-30	4.26
2020-06-30	4.07
2020-03-31	4.49
2019-12-31	8.13
2019-09-30	6.64
2019-06-30	9.14
2019-03-31	11.60
2018-12-31	6.90
2018-09-30	8.43
2018-06-30	8.23
2018-03-31	10.06
2017-12-31	3.43
2017-09-30	6.08
2017-06-30	6.70
2017-03-31	8.59
2016-12-31	8.27
2016-09-30	9.37
2016-06-30	12.85
2016-03-31	14.40
2015-12-31	16.13
2015-09-30	23.53
2015-06-30	14.61
2015-03-31	24.61
2014-12-31	14.98
2014-09-30	18.67
2014-06-30	17.69
2014-03-31	24.91
2013-12-31	9.33
2013-09-30	11.89
2013-06-30	0.00
2013-03-31	0.00
2012-12-31	27.12

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

1.56

2026-03-31

1.85

2025-12-31

2.34

2025-09-30

1.74

2025-06-30

2.30

2025-03-31

2.24

2024-12-31

2.24

2024-09-30

2.65

2024-06-30

3.39

2024-03-31

2.28

2023-12-31

2.49

2023-09-30

2.23

2023-06-30

2.76

2023-03-31

3.39

2022-12-31

3.28

2022-09-30

4.36

2022-06-30

2.98

2022-03-31

4.12

2021-12-31

4.63

2021-09-30

6.12

2021-06-30

7.35

2021-03-31

8.33

2020-12-31

6.76

2020-09-30

4.26

2020-06-30

4.07

2020-03-31

4.49

2019-12-31

8.13

2019-09-30

6.64

2019-06-30

9.14

2019-03-31

11.60

2018-12-31

6.90

2018-09-30

8.43

2018-06-30

8.23

2018-03-31

10.06

2017-12-31

3.43

2017-09-30

6.08

2017-06-30

6.70

2017-03-31

8.59

2016-12-31

8.27

2016-09-30

9.37

2016-06-30

12.85

2016-03-31

14.40

2015-12-31

16.13

2015-09-30

23.53

2015-06-30

14.61

2015-03-31

24.61

2014-12-31

14.98

2014-09-30

18.67

2014-06-30

17.69

2014-03-31

24.91

2013-12-31

9.33

2013-09-30

11.89

2013-06-30

0.00

2013-03-31

0.00

2012-12-31

27.12

Quick Ratio (Acid-Test): 1.56

RARE Quick Ratio

RARE Average Quick Ratio (Acid-Test) Chart

RARE Current vs Average Quick Ratio (Acid-Test) Chart

RARE Quick Ratio (Acid-Test) Metrics

RARE Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

RARE Quick Ratio (Acid-Test) History

Related Metrics